Dysregulated BMP‐10 signaling contributes to cardiovascular diseases and cancer, highlighting the need to control ALK1‐mediated endothelial responses to BMP‐10 for therapeutic development. This evidence concerns the gene BMP10 and cardiovascular disorder.